Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration

Sponsor
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Study ID
NCT00710229
Phase
PHASE3
Status
Unknown

Conditions

  • Age Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Angiogenesis plays a key role in the development of choroidal neovascularizations (CNV) in age-related macular degeneration. Vascular endothelial growth factor (VEGF) is the most important factor involved in this angiogenetic processes in the eye. This forms the basis for new therapeutic interventions in exudative AMD. Currently two drugs have been approved by the FDA and one drug is used off-label. All these drugs are administered intravitreally. The present study aims to directly compare the effects ranibizumab and bevacizumab in a randomized controlled study in patients with neovascular AMD.

Key Dates

First listed
Jul 4, 2008
Start date
Jul 31, 2008
Status verified
Jun 2010
Primary completion
Dec 31, 2011

Study Design

Enrollment
320 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: A
    Intravitreal injectin of Ranibizumab (3 monthly injection followed by monthly injectins as long as required
  • Active Comparator: B
    Intravitreal injectin of Bevacizumab (3 monthly injection followed by monthly injectins as long as required

Primary Outcome Measure

Change of visual acuity over time [ Time Frame: 12 months ]

Central Contacts

Related Studies